ArticleMarine drugs2020
Putative Inhibitors of SARS-CoV-2 Main Protease from A Library of Marine Natural Products: A Virtual Screening and Molecular Modeling Study.
Article in Marine drugs, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 152 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
152 citing papers in PubMed, 323 citations in OpenAlex.
- Mechanistic role of gut microbiota metabolites in hypertension-insomnia comorbidity via integrated network pharmacology and molecular dynamics.Scientific reports · 2026Article
- Multifaceted Marine Peptides and Their Therapeutic Potential.Marine drugs · 2025Review
- Synthesis, Biological Evaluation, Molecular Dynamics, and QM-MM Calculation of Spiro-Acridine Derivatives Against Leishmaniasis.Microorganisms · 2025Article
- Identification of potential MMP-8 inhibitors through virtual screening of natural product databases.In silico pharmacology · 2025Article
- Design, Synthesis, and Evaluation of Novel (-)-cis-N-Normetazocine Derivatives: In Vitro and Molecular Modeling Insights.Chemical biology & drug design · 2024Article
- New Pyrimidinone Bearing Aminomethylenes and Schiff Bases as Potent Antioxidant, Antibacterial, SARS-CoV-2, and COVID-19 Main Protease MACS omega · 2024Article
- Role of marine natural products in the development of antiviral agents against SARS-CoV-2: potential and prospects.Marine life science & technology · 2024Review
- Marine-Derived Bioactive Metabolites as a Potential Therapeutic Intervention in Managing Viral Diseases: Insights from the SARS-CoV-2 In Silico and Pre-Clinical Studies.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Targeting Viral and Cellular Cysteine Proteases for Treatment of New Variants of SARS-CoV-2.Viruses · 2024Article
- Discovery of Pyrano[2,3-Pharmaceuticals (Basel, Switzerland) · 2024Article
- Marine natural products and human immunity: novel biomedical resources for anti-infection of SARS-CoV-2 and related cardiovascular disease.Natural products and bioprospecting · 2024Review
- The Potential Roles ofCurrent computer-aided drug design · 2024Article
- Chromone-embedded peptidomimetics and furopyrimidines as highly potent SARS-CoV-2 infection inhibitors: docking and MD simulation study.BMC research notes · 2023Article
- An overview on medicinal plants used for combating coronavirus: Current potentials and challenges.Journal of agriculture and food research · 2023Article
- Studies on the Nonalkaloidal Secondary Metabolites ofACS omega · 2023Article
- COVID-19 associated thyroid dysfunction and other comorbidities and its management using phytochemical-based therapeutics: a natural way.Bioscience reports · 2023Review
- SARS2Mutant: SARS-CoV-2 amino-acid mutation atlas database.NAR genomics and bioinformatics · 2023Article
- Drug target of natural products and COVID-19: how far has science progressed?Annals of medicine and surgery (2012) · 2023Article
- Review
- Ultrasound assisted Cu-catalyzed Ullmann-Goldberg type coupling-cyclization in a single pot: Synthesis andJournal of molecular structure · 2023Article
92 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The current emergency due to the worldwide spread of the COVID-19 caused by the new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a great concern for global public health. Already in the past, the outbreak of severe acute respiratory syndrome (SARS) in 2003 and Middle Eastern respiratory syndrome (MERS) in 2012 demonstrates the potential of coronaviruses to cross-species borders and further underlines the importance of identifying new-targeted drugs. An ideal antiviral agent should target essential proteins involved in the lifecycle of SARS-CoV. Currently, some HIV protease inhibitors (i.e., Lopinavir) are proposed for the treatment of COVID-19, although their effectiveness has not yet been assessed. The main protease (M
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.